Glutamate receptor ionotropic, NMDA 1 glycine modulatory site (GluN1 glycine site)

The Glutamate receptor ionotropic, NMDA 1 (GluN1) glycine modulatory site is a critical regulatory locus within the NMDA receptor complex, a primary mediator of excitatory neurotransmission in the central nervous system (Traynelis et al., 2010). Unlike the glutamate-binding site located on GluN2 subunits, the GluN1 site binds glycine or D-serine, which act as essential co-agonists required for channel opening (Johnson and Ascher, 1987; Furukawa and Gouaux, 2003). Activation of this site is necessary for synaptic plasticity, long-term potentiation, and cognitive processes such as learning and memory (Paoletti et al., 2013). Dysregulation of NMDA receptor activity via this site is implicated in various neurological and psychiatric conditions, including schizophrenia, where hypofunction is a hypothesized cause of negative symptoms and cognitive deficits (Javitt, 2010). Pharmacological targeting of the glycine site includes agonists and partial agonists like D-cycloserine and rapastinel to enhance NMDA function in cognitive disorders, as well as antagonists like gavestinel to prevent excitotoxicity in stroke or pain (Moskal et al., 2017; Lees, 2000). Because it modulates the receptor's response to glutamate without directly opening the channel, it offers a fine-tuning approach to therapeutic intervention with potentially fewer side effects than direct pore blockers (Hansen et al., 2021).

Other names

Strychnine-insensitive glycine siteNMDA receptor glycine siteGRIN1 glycine siteNR1 glycine siteGlycine-B site

Co-agonist activation, partial agonism, or antagonism of the NMDA receptor complex to modulate excitatory signaling.